English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

BeiGene In-Licenses Two Potential Cancer Drugs from Janssen

Oct. 13, 2011

The Chinese pharmaceutical company BeiGene announced on October 14 that it has entered into an exclusive in-licensing and co-development agreement with Janssen Pharmaceutica NV, a division of Johnson & Johnson, for two clinical-stage oncology compounds. Founded last year, BeiGene has an ambitious two-pronged business plan that combines in-licensing of five clinical stage drug candidates with developing its own novel drugs. The two drug candidates, intetumumab and MTKi-327, are the first acquisitions the company has made.